Domination Number of the Non-commuting Graph of Finite Groups

Let G be a non-abelian group. The non-commuting graph of group G, shown by ΓG, is a graph with the vertex set G \ Z(G), where Z(G) is the center of group G. Also two distinct vertices of a and b are adjacent whenever ab ≠ ba. A set S ⊆ V(Γ) of vertices in a graph Γ is a dominating set if every vertex v ∈ V(Γ) is an element of S or adjacent to an element of S. The domination number of a graph Γ denoted by γ(Γ), is the minimum size of a dominating set of Γ. </p><p>Here, we study some properties of the non-commuting graph of some finite groups. In this paper, we show that \gamma(\Gamma_G)<\frac{|G|-|Z(G)|}{2}. Also we charactrize all of groups G of order n with t = ∣Z(G)∣, in which $\gamma(\Gamma_{G})+\gamma(\overline{\Gamma}_{G})\in \{n-t+1,n-t,n-t-1,n-t-2\}.

Neutralization of Lethal Potency of Tetanus Toxin using Phage Display Produced scFv Antibody

Background and Aim: Phage display technology provides a new approach for making human antibody fragments that could be applicable in passive immune therapy. We applied the use of this technology to make human single-chain variable fragments (scFvs) specific for tetanus toxin. Tetanus toxin is a neurotoxin constituted by the association of two subunits, mediates its lethal action by blocking neuromuscular vesicle docking. Methods: We previously found that six Human scFv clones inhibit toxin binding to ganglioside GT1b. This is the final report of human tetanus scFvs (scFv 8 and scFv 13) isolated from an immunized library of more than 106 scFv clones with in vivo neutralizing activity. Results: Only scFv 13 can reduce the in vivo toxicity induced by tetanus toxin. Also, scFv 8 has a weak capability of reducing the in vivo toxicity of the toxin. Conclusion: These selected ScFvs can be considered as a possible option to substitute the human tetanus immunoglobulin (HTIG) which is extensively current immunotherapy for tetanus patients. Taken together, our results suggest that the use of human tetanus scFvs may lead to a less aggressive passive immune therapy against tetanus. *Corresponding Author: Mahdi Aminian; Email: [email protected] Please cite this article as: Khalili E, Abbasi E, Aminian M. Neutralization of Lethal Potency of Tetanus Toxin using Phage Display Produced ScFv Antibody.Arch Med Lab Sci. 2021;7:(e3). https://doi.org/10.22037/amls.v7.3378

Deep Learning Model With Adaptive Regularization for EEG-Based Emotion Recognition Using Temporal and Frequency Features

Since EEG signal acquisition is non-invasive and portable, it is convenient to be used for different applications. Recognizing emotions based on Brain-Computer Interface (BCI) is an important active BCI paradigm for recognizing the inner state of persons. There are extensive studies about emotion recognition, most of which heavily rely on staged complex handcrafted EEG feature extraction and classifier design. In this paper, we propose a hybrid multi-input deep model with convolution neural networks (CNNs) and bidirectional Long Short-term Memory (Bi-LSTM). CNNs extract time-invariant features from raw EEG data, and Bi-LSTM allows long-range lateral interactions between features. First, we propose a novel hybrid multi-input deep learning approach for emotion recognition from raw EEG signals. Second, in the first layers, we use two CNNs with small and large filter sizes to extract temporal and frequency features from each raw EEG epoch of 62-channel 2-s and merge with differential entropy of EEG band. Third, we apply the adaptive regularization method over each parallel CNN’s layer to consider the spatial information of EEG acquisition electrodes. The proposed method is evaluated on two public datasets, SEED and DEAP. Our results show that our technique can significantly improve the accuracy in comparison with the baseline where no adaptive regularization techniques are used

Medium Optimization for Synaptobrevin Production Using Statistical Methods

Background: Botulinum toxin, the most potent biological toxin, has become a powerful therapeutic tool for a growing number of clinical applications. Molecular studies have identified a family of synaptic vesicle-associated membrane proteins (VAMPs, also known as synaptobrevins) which have been implicated in synaptic vesicle docking and fusion with plasma membrane proteins.Materials and Methods: Using the synaptobrevin as a substrate for in vitro assay is the method to detect BoNT activity. We have been working on optimizations of bacterial expression conditions and media for high-level production of synaptobrevin peptide. Statistics-based experimental design was used to investigate the effect of medium components (E. coli strain, peptone, IPTG, yeast extract, ampicillin, and temperature) on synaptobrevin production by E. coli.Results: A 24 fractional factorial design with center points revealed that IPTG and temperature were the most significant factors, whereas the other factors were not important within the levels tested. This purpose was followed by a central composite design to develop a response surface for medium optimization. The optimum medium composition for synaptobrevin production was found to be: IPTG 29 mM, peptone 10 g/L, yeast extract 5 g/L, temperature 23°C and ampicillin 100 mg/L. This medium was projected to produce, theoretically, 115 mg/Lsynaptobrevin.Conclusion: The optimum medium composition synaptobrevin production was found to be: BL21 (E.coli strain), LB medium (peptone 10 g/L, Yeast 5 g/L), Ampicillin (100 mg/L), IPTG (0.29 mg/L) and temperature (23°C)

Differentiation between metastatic and tumour-free cervical lymph nodes in patients with papillary thyroid carcinoma by grey-scale sonographic texture analysis

Purpose: Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, and cervical lymph nodes (LNs) are the most common extrathyroid metastatic involvement. Early detection and reliable diagnosis of LNs can lead to improved cure rates and management costs. This study explored the potential of texture analysis for texture-based classification of tumour-free and metastatic cervical LNs of PTC in ultrasound imaging. Material and methods: A total of 274 LNs (137 tumour-free and 137 metastatic) were explored using the texture analysis (TA) method. Up to 300 features were extracted for texture analysis in three normalisations (default, 3sigma, and 1-99%). Linear discriminant analysis was employed to transform raw data to lower-dimensional spaces and increase discriminative power. The features were classified by the first nearest neighbour classifier. Results: Normalisation reflected improvement on the performance of the classifier; hence, the features under 3sigma normalisation schemes through FFPA (fusion Fisher plus the probability of classification error [POE] + average correlation coefficients [ACC]) features indicated high performance in classifying tumour-free and metastatic LNs with a sensitivity of 99.27%, specificity of 98.54%, accuracy of 98.90%, positive predictive value of 98.55%, and negative predictive value of 99.26%. The area under the receiver operating characteristic curve was 0.996. Conclusions: TA was determined to be a reliable method with the potential for characterisation. This method can be applied by physicians to differentiate between tumour-free and metastatic LNs in patients with PTC in conventional ultrasound imaging

Fabrication and characterization of polymer-based nanocomposite membrane modified by magnetite nanoparticles for Cd2+^{{2+}} and Pb2+^{{2+}} removal from aqueous solutions

In the present work, a polyvinyl chloride (PVC)/magnetite nanocomposite membrane (NCM) was fabricated by a casting technique for the removal of Cd2+ and Pb2+ ions from aqueous solutions. Magnetite (Fe3O4) nanoparticles (NPs) were synthesized from the Ramalina sinensis plant extract. The synthesized materials were characterized by UV–visible, X-ray diffraction, Fourier-transform infrared, field emission scanning electron microscopy, energy-dispersive X-Ray spectrometry, Brunauer–Emmett–Teller (BET) surface area analysis, vibrating sample magnetometry, and thermal gravimetric analysis techniques. The fabricated NCM enhanced the adsorption capability of PVC without the use of any catalyst. The size of the magnetite NPs distributed in the NCM structure varied in the range of 25–70 nm. The specific surface area of the fabricated NCM was found to be $5.670~\mathrm{m}^{2}{\cdot }\mathrm{g}^{-1}$, which is approximately thrice greater than the reported value for pure PVC. The removal process of both Cd2+ and Pb2+ ions from aqueous solution showed the best fit to the Langmuir isotherm model. The maximum adsorption capacities of cadmium and lead ions were estimated to be 11.55 and $11.40~\mathrm{mg}{\cdot }\mathrm{g}^{-1}$, respectively. A kinetic investigation showed that the removal process of both metal ions can be well described by the pseudo-second-order kinetic model. The results obtained from adsorption investigations revealed that the synthesized NCM can be used for the removal of Cd2+ and Pb2+ ions from aqueous media

Fabrication and characterization of polymer-based nanocomposite membrane modified by magnetite nanoparticles for Cd2+^{{2+}} and Pb2+^{{2+}} removal from aqueous solutions

In the present work, a polyvinyl chloride (PVC)/magnetite nanocomposite membrane (NCM) was fabricated by a casting technique for the removal of Cd2+ and Pb2+ ions from aqueous solutions. Magnetite (Fe3O4) nanoparticles (NPs) were synthesized from the Ramalina sinensis plant extract. The synthesized materials were characterized by UV–visible, X-ray diffraction, Fourier-transform infrared, field emission scanning electron microscopy, energy-dispersive X-Ray spectrometry, Brunauer–Emmett–Teller (BET) surface area analysis, vibrating sample magnetometry, and thermal gravimetric analysis techniques. The fabricated NCM enhanced the adsorption capability of PVC without the use of any catalyst. The size of the magnetite NPs distributed in the NCM structure varied in the range of 25–70 nm. The specific surface area of the fabricated NCM was found to be $5.670~\mathrm{m}^{2}{\cdot }\mathrm{g}^{-1}$, which is approximately thrice greater than the reported value for pure PVC. The removal process of both Cd2+ and Pb2+ ions from aqueous solution showed the best fit to the Langmuir isotherm model. The maximum adsorption capacities of cadmium and lead ions were estimated to be 11.55 and $11.40~\mathrm{mg}{\cdot }\mathrm{g}^{-1}$, respectively. A kinetic investigation showed that the removal process of both metal ions can be well described by the pseudo-second-order kinetic model. The results obtained from adsorption investigations revealed that the synthesized NCM can be used for the removal of Cd2+ and Pb2+ ions from aqueous media

Laparoscopy in management of appendicitis in high-, middle-, and low-income countries: a multicenter, prospective, cohort study.

BACKGROUND: Appendicitis is the most common abdominal surgical emergency worldwide. Differences between high- and low-income settings in the availability of laparoscopic appendectomy, alternative management choices, and outcomes are poorly described. The aim was to identify variation in surgical management and outcomes of appendicitis within low-, middle-, and high-Human Development Index (HDI) countries worldwide. METHODS: This is a multicenter, international prospective cohort study. Consecutive sampling of patients undergoing emergency appendectomy over 6 months was conducted. Follow-up lasted 30 days. RESULTS: 4546 patients from 52 countries underwent appendectomy (2499 high-, 1540 middle-, and 507 low-HDI groups). Surgical site infection (SSI) rates were higher in low-HDI (OR 2.57, 95% CI 1.33-4.99, p = 0.005) but not middle-HDI countries (OR 1.38, 95% CI 0.76-2.52, p = 0.291), compared with high-HDI countries after adjustment. A laparoscopic approach was common in high-HDI countries (1693/2499, 67.7%), but infrequent in low-HDI (41/507, 8.1%) and middle-HDI (132/1540, 8.6%) groups. After accounting for case-mix, laparoscopy was still associated with fewer overall complications (OR 0.55, 95% CI 0.42-0.71, p < 0.001) and SSIs (OR 0.22, 95% CI 0.14-0.33, p < 0.001). In propensity-score matched groups within low-/middle-HDI countries, laparoscopy was still associated with fewer overall complications (OR 0.23 95% CI 0.11-0.44) and SSI (OR 0.21 95% CI 0.09-0.45). CONCLUSION: A laparoscopic approach is associated with better outcomes and availability appears to differ by country HDI. Despite the profound clinical, operational, and financial barriers to its widespread introduction, laparoscopy could significantly improve outcomes for patients in low-resource environments. TRIAL REGISTRATION: NCT02179112

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

The global burden of adolescent and young adult cancer in 2019 : a systematic analysis for the Global Burden of Disease Study 2019

Background In estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults. Methods Using the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults. Findings There were 1.19 million (95% UI 1.11-1.28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59.6 [54.5-65.7] per 100 000 person-years) and high-middle SDI countries (53.2 [48.8-57.9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14.2 [12.9-15.6] per 100 000 person-years) and middle SDI (13.6 [12.6-14.8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23.5 million (21.9-25.2) DALYs to the global burden of disease, of which 2.7% (1.9-3.6) came from YLDs and 97.3% (96.4-98.1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally. Interpretation Adolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe